Consistently, CTLA4 blockade with the CTLA4–specific antibody ipilimumabTM leads to increased T cell-mediated effector responses and induces cancer regression in clinical trials of patients with metastatic melanoma [29]. Here, CTLA4 is linked to metastatic melanoma.